Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY11.64
+0.19 (+1.66%)
CN SHH Healthcare Biotechnology
Address
Xiayun Industrial Park 561100
Anshun, CN
Anshun, CN
CEO
Qianfan Zhang
Website
gz-sanli.com
IPO
2020-04-28
ISIN CNE1000040B4
Description
This pharmaceutical enterprise is dedicated to the comprehensive process of developing, manufacturing, and distributing medicinal products. Its diverse portfolio includes therapeutic solutions for children, respiratory ailments, cardiovascular and cerebrovascular disorders, digestive issues, trauma recovery, rehabilitation needs, and ophthalmic conditions. The company commenced operations in 1995 and maintains its primary base in Guiyang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY11.64
+0.19 (+1.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14M
Beta
0.98
Float Shares
181.63M
Free Float %
45.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.00% | +12.59% | +44.71% | +34.99% | +35.89% | +39.15% | +34.77% | -11.28% | +5.03% | +53.88% | +53.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.64
DCF (Unlevered)
10.19
-12.4%
DCF (Levered)
20.05
+72.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.21
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-20.6% Q1'26: -6.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-83.6% Q1'26: +10.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.6% Q1'26: +2.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+4.6% ★ Q1'26: +14.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.1% ★ Q1'26: +10.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.8% ★ Q1'26: -3.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.57× Q1'26: 2.89× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
938.97M
est: 944.00M (-0.5%)
|
1.20B
est: 1.22B (-1.5%)
|
1.63B
est: 1.92B (-15.0%)
|
2.14B
est: 2.16B (-0.6%)
|
1.70B
est: 1.46B (+16.8%)
|
1.52B
1.52B – 1.52B
+4.5% YoY
|
1.59B
1.59B – 1.59B
+4.5% YoY
|
| EBITDA |
196.19M
est: 192.09M (+2.1%)
|
243.68M
est: 248.25M (-1.8%)
|
374.61M
est: 355.50M (+5.4%)
|
413.63M
est: 398.44M (+3.8%)
|
152.90M
est: 269.32M (-43.2%)
|
281.51M
281.51M – 281.51M
+4.5% YoY
|
294.26M
294.26M – 294.26M
+4.5% YoY
|
| EBIT |
185.01M
est: 173.59M (+6.6%)
|
227.86M
est: 224.34M (+1.6%)
|
338.19M
est: 307.26M (+10.1%)
|
339.67M
est: 344.37M (-1.4%)
|
78.84M
est: 232.77M (-66.1%)
|
243.31M
243.31M – 243.31M
+4.5% YoY
|
254.33M
254.33M – 254.33M
+4.5% YoY
|
| Net Income |
152.28M
est: 151.33M (+0.6%)
|
201.28M
est: 179.96M (+11.9%)
|
292.70M
est: 315.03M (-7.1%)
|
274.03M
est: 349.01M (-21.5%)
|
46.25M
est: 143.64M (-67.8%)
|
151.38M
151.38M – 151.38M
+5.4% YoY
|
163.99M
163.99M – 163.99M
+8.3% YoY
|
| SGA |
492.75M
est: 436.44M (+12.9%)
|
618.01M
est: 564.05M (+9.6%)
|
879.21M
est: 948.58M (-7.3%)
|
1.09B
est: 1.06B (+2.5%)
|
646.17M
est: 718.63M (-10.1%)
|
751.16M
751.16M – 751.16M
+4.5% YoY
|
785.17M
785.17M – 785.17M
+4.5% YoY
|
| EPS |
0.37
est: 0.37 (+0.0%)
|
0.49
est: 0.44 (+11.4%)
|
0.71
est: 0.75 (-5.2%)
|
0.67
est: 0.83 (-19.3%)
|
0.11
est: 0.34 (-67.6%)
|
0.36
0.36 – 0.36
+5.9% YoY
|
0.39
0.39 – 0.39
+8.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
50.21M
OE per share TTM
0.12
Owner's Yield
0.76%
Maintenance CapEx ratio
27.23%
Maint CapEx / Avg PPE
25.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 85.4K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 74.4K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 63.8K | 0.28% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 2.0K | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
27.6K
Shares Outstanding
401.06M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongyu Zhang | Deputy General Manager | — | female |
| Jing Long | Chairman of the Supervisory Board & Manager of Human Resources Department | — | female |
| Jue Ben Wang | Vice Chairman & Deputy GM | — | male |
| Ke Guo | Financial Director, Accounting Supervisor & Director | — | female |
| Li Deng | Deputy General Manager | — | male |
| Qianfan Zhang | GM, Vice Chairman & Board Secretary | — | male |
| Yi Wang | Deputy GM & Director | — | male |
| Yuan Yu | Deputy General Manager | — | male |
| Zhan Biao Luo | Deputy General Manager | — | male |
| Zhiyu Yang | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603439.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
